SCHEDULE: Davidson Kempner Entities Report 0% Stake in Blueprint Medicines Corp

Davidson Kempner Capital Management and its affiliates, including Anthony A. Yoseloff, have filed a Schedule 13G indicating they hold no beneficial ownership in Blueprint Medicines Corp as of July 14, 2025.

Summary

• M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities and Relative Value LP, Davidson Kempner Capital Management LP, and Anthony A. Yoseloff (collectively, the "Reporting Persons") filed a Schedule 13G.
• The filing indicates that as of July 14, 2025, the Reporting Persons beneficially own 0.00 shares of Blueprint Medicines Corp's Common Stock.
• This represents 0% of the class of securities outstanding.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing disclosing beneficial ownership. The 0% ownership indicates no significant stake, which is neither positive nor negative for the issuer's prospects.

Future Outlook

NA

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Blueprint Medicines Corp, nor were they acquired or held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not provide specific industry context or trends. It merely reports the ownership stake of a specific investment group in a biotechnology company.

Key Dates

Keywords

Blueprint Medicines Corp, Schedule 13G, Beneficial Ownership, Davidson Kempner Capital Management, Anthony A. Yoseloff, Common Stock, SEC Filing, Institutional Ownership